Hansen Gwenn 4

What Happened
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), had RSUs vest on April 30, 2026. The Form 4 shows conversion/exercise of RSU-related derivatives totaling 8,608 shares (2,000; 3,750; 2,858) at $0 per share, and an open-market sale of 3,214 common shares at a weighted average price of $16.65 for total proceeds of $53,498. The sale was a sell-to-cover to satisfy tax withholding tied to the RSU vesting, not a discretionary cash grab.

Key Details

• Transaction date: 2026-04-30 (Form filed 2026-04-30). Filing appears timely.
• Sale: 3,214 shares disposed in an open-market sale; weighted average price $16.65; proceeds $53,498. Price range reported: $16.51–$16.78. (Footnote F2)
• Conversions/Acquisitions: three derivative exercises/conversions (M) for 2,000; 3,750; and 2,858 shares (total 8,608) at $0 (reflecting RSU settlement). Matching derivative disposition lines reflect the RSU settlement process.
• Shares owned after the transactions: not specified in the information provided on this Form 4.
• Notable footnotes: F1 states the sale was required by the issuer’s sell-to-cover tax withholding election (i.e., mandated to cover taxes). F3–F7 explain these were RSUs that vest quarterly over three years (1/12 each quarter) and convert to shares on vesting.

Context
This was a routine sell-to-cover following RSU vesting: RSUs converted to shares and a portion immediately sold to satisfy tax withholding. Such transactions are common and generally reflect tax mechanics rather than a signal about the officer’s view on the company. Purchases would typically be more indicative of insider conviction.